Asahikawa, Japan

Asahikawa Medical College

www.asahikawa-med.ac.jp
Asahikawa, Japan

Asahikawa Medical College , or Kyokui , was a national university in Japan. It was renamed Asahikawa Medical University. Wikipedia.


Time filter

Source Type

Patent
Asahikawa Medical College and Tsumura & Co. | Date: 2010-10-27

It is an object of the invention to discover a substance that effectively increases the production of adrenomedullin, as well as to provide an adrenomedullin production-enhancing agent utilizing this substance. The adrenomedullin production-enhancing agent is characterized by inclusion of a ginsenoside, a sanshool, and/or a shogaol as active ingredients.


Patent
Asahikawa Medical College and TSUMURA & Co. | Date: 2015-09-25

It is an object of the invention to discover a substance that effectively increases the production of adrenomedullin, as well as to provide an adrenomedullin production-enhancing agent utilizing this substance. The adrenomedullin production-enhancing agent is characterized by inclusion of a ginsenoside, a sanshool, and/or a shogaol as active ingredients.


Patent
Asahikawa Medical College and Fuso Pharmaceutical Industries Ltd. | Date: 2011-04-15

Disclosed is the novel hCL-K1 polypeptide which offers collectin activity. This polypeptide consists of consecutive 271 amino acids set out in SEQ ID NO: 2 and does not bind to both maltose and N-acetylgalactosamine.


Hosaka M.,Gunma University | Watanabe T.,Asahikawa Medical College
Endocrine Journal | Year: 2010

Secretory granules in endocrine cells selectively store bioactive peptide hormones and amines, which are secreted in a regulated manner upon appropriate stimulation. In addition to bioactive substances, various proteins and lipids characteristic of secretory granules are likely recruited to a restricted space at the trans-Golgi Network (TGN), and the space then matures to the secretory granule. Although experimental findings so far have strongly suggested that aggregation- and receptor-mediated processes are essential for the formation of secretory granules, the putative link between these two processes remains to be clarified. Recently, secretogranin III (SgIII) has been identified as a specific binding protein for chromogranin A (CgA), a representative constituent of the core aggregate within secretory granules, and it was later revealed that SgIII can also bind to the cholesterol-rich membrane domain at the TGN. Based on its multifaceted binding properties, SgIII may act as a central player in the formation of cholesterol-rich membrane platforms. Upon these platforms, essential processes for secretory granule biogenesis coordinately occur; that is, selective recruitment of prohormones, processing and modifying of prohormones, and condensation of mature hormones as an aggregate. This review summarizes the findings and theoretical concepts on the issue to date and then focuses on the putative role of SgIII in secretory granule biogenesis in endocrine cells.


Yoshida S.,Asahikawa Medical College
Biological Chemistry | Year: 2010

Klk8 is a tryptic serine protease with limited substrate specificity. Klk8 mRNA is expressed in many developing organs, whereas its expression is confined to limited regions, including the hippocampus, in adults. In the hippocampus, Klk8 is involved in activity-dependent synaptic changes such as long-term potentiation, which was found to be suppressed in Klk8 knockout (KO) mice. Oligodendrocytes only expressed Klk8 mRNA after injury to the central nervous system. The epidermis of the skin is one of the tissues that exhibits a high level of KLK8 expression. Klk8 might be involved in desquamation through the degradation of adhesive molecules that connect layers of the epidermis. Klk8 might thus be involved in tissue development and rearrangement. Copyright © 2010 by Walter de Gruyter Berlin New York.


Palmoplantar pustulosis (PPP) is famous for causing typical tonsillar focal diseases. Clinical improvement of PPP rash after tonsillectomy was seen in 109 (94%) of 116 patients by subjective self-assessment, and 52 (88%) of 59 patients by objective Palmoplantar Pustulosis Area and Severity Index (PPPASI) scoring. Flow-cytometric analyses revealed that expression of activation markers (CD25 and HLA) class II increased on tonsillar T cells from PPP and IgAN patients. Moreover, expressions of skin-homing receptors (CLA and CCR6) increased on tonsillar T cells from PPP patients. In addition, the expressions were enhanced by stimulation of indigenous bacteria. Moreover, those expressions also increased in peripheral T cells, and decreased after tonsillectomy. Immunohistchemical analyses revealed that the ligands of those receptors (E-selectin and chemokine ligand 20) were expressed in lesions of skin. On the basis of our findings, migration of tonsillar T cells on which several homing receptors express by hyperimmune response against indigenous bacteria have a critical role in the pathogenesis of tonsillar focal diseases. Copyright © 2011 S. Karger AG, Basel.


Okumura T.,Asahikawa Medical College | Tanno S.,Asahikawa Medical College | Ohhira M.,Asahikawa Medical College
Journal of Gastroenterology | Year: 2010

Background: Since little is known about the prevalence of patients with functional gastrointestinal disorders (FGID), this study was performed to clarify the prevalence of FGID, especially functional dyspepsia (FD), in new patients of an outpatient clinic with primary care physicians in Japan. Methods: We analyzed consecutive outpatients (n = 5183) who first visited the Department of General Medicine, Asahikawa Medical College Hospital, between April 2004 and March 2009. Results: Out of 5813 patients, 818 (14.1%) visited because of abdominal symptoms. Final diagnoses of the 818 patients were FGID (n = 320, 39.1%), organic gastrointestinal diseases (n = 237, 28.9%), organic non-GI disease (n = 135, 16.5%), and others (n = 126, 15.4%). The 320 patients with FGID had FD (n = 170), irritable bowel syndrome (IBS) (n = 68), and other FGIDs (n = 88). The rate of FGID or FD in all patients was 5.5% or 2.9%, respectively. Among outpatients (n = 381) who complained of upper abdominal symptoms, approximately 45% had FD. There was no gender difference in the frequency of FGID, FD, or IBS in all ages of patients. A lower incidence of FD was shown in female patients over 70 years old and a higher incidence of IBS in male patients under 29 years old. Discussion: These results suggest that the prevalence of FGID, especially FD, is very high in an outpatient clinic with primary care physicians in Japan. © 2009 Springer.


Kawabe J.,Asahikawa Medical College | Ushikubi F.,Asahikawa Medical College | Hasebe N.,Asahikawa Medical College
Circulation Journal | Year: 2010

Prostacyclin (PGI2) is one of the important vascular prostanoids, the effects of which counteract those of throm-boxane (TXA2), and these 2 prostanoids provide an important balance in cardiovascular homeostasis. The clinical experience of COX-2 selective inhibitors having unexpected adverse effects in patients with cardiovascular risk has opened up a debate about the role of COX-2-derived prostanoids in vascular pathophysiology. PGI2 is a major anti-atherogenic prostanoid produced by COX-2 in vascular cells, including endothelial and vascular smooth muscle cells. The balance between COX-2-derived PGI2, COX-1-derived TXA2, and other COX-2-mediated atherogenic prostanoids is a crucial factor in determining pathophysiological outcomes. Recent studies using stable PGI2 analogs and genetically deficient mice have revealed novel effects of PGI2 on its target cells, such as endothelial and endothelial progenitor cells. The role PGI2 in the physiology and pathophysiology of vascular diseases is reviewed and the recent findings linking PGI2, COX-2 and atherothrombosis are summarized.


The present invention provides an iron chelating agent which can selectively chelate iron ions. The iron chelating agent of the present invention includes a compound represented by the following formula (1) or a salt thereof^(1) represents an alkylene group; R^(2) and R^(3) each independently represent a hydrogen atom, a hydrocarbon group or a group having chelating ability; and the total coordination number of the groups represented by R^(2) and R^(3) is 1 or 2.


Patent
Asahikawa Medical College | Date: 2010-03-17

It is intended to provide anticancer therapy using autologous cells or the like, which induces the regression of cancer or has favorable drug delivery effects and brings about reduction or withdrawal of a hypoxic region(s) in tumor. Transplantation of endothelial progenitor cells, via intravenously or other methods leads to tumor growth inhibition, an increase of the vascular density with an enlargement of the vascular diameter, and reduction of a hypoxic region(s) in the tumor. Allogeneic transplantation of endothelial progenitor cells may be achieved to secure the cells for the therapy, however, autologous transplantation of endothelial progenitor cells from cancer patients would be desirable in order to evade rejection. When the autologous cells are used, mononuclear cells are separated from the peripheral blood or bone marrow of the patient and cultured using an endothelial differentiation medium containing cytokines such as VEGF to obtain adherent cells, which can then be collected and advantageously used as endothelial progenitor cells.

Loading Asahikawa Medical College collaborators
Loading Asahikawa Medical College collaborators